Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy

N. L. Henry, A. Nguyen, F. Azzouz, L. Li, J. Robarge, S. Philips, D. Cao, T. C. Skaar, J. M. Rae, A. M. Storniolo, D. A. Flockhart, D. F. Hayes, V. Stearns

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Background: Tamoxifen, a selective oestrogen receptor (ER) modulator, increases bone mineral density (BMD) in postmenopausal women and decreases BMD in premenopausal women. We hypothesised that inherited variants in candidate genes involved in oestrogen signalling and tamoxifen metabolism might be associated with tamoxifen effects in bone. Methods: A total of 297 women who were initiating tamoxifen therapy were enrolled in a prospective multicentre clinical trial. Lumbar spine and total hip BMD values were measured using dual-energy X-ray absorptiometry (DXA) at baseline and after 12 months of tamoxifen therapy. Single-nucleotide polymorphisms (SNPs) in ESR1, ESR2, and CYP2D6 were tested for associations in the context of menopausal status and previous chemotherapy, with a mean percentage change in BMD over 12 months. Results: The percentage increase in BMD was greater in postmenopausal women and in those patients who had been treated with chemotherapy. No significant associations between tested SNPs and either baseline BMD or change in BMD with 1 year of tamoxifen therapy were detected. Conclusion: The evaluated SNPs in ESR and CYP2D6 do not seem to influence BMD in tamoxifen-treated subjects.

Original languageEnglish (US)
Pages (from-to)294-300
Number of pages7
JournalBritish Journal of Cancer
Volume102
Issue number2
DOIs
StatePublished - Jan 1 2010

Keywords

  • Bone mineral density
  • Chemotherapy
  • CYP2D6
  • Oestrogen receptor
  • Polymorphism
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy'. Together they form a unique fingerprint.

  • Cite this

    Henry, N. L., Nguyen, A., Azzouz, F., Li, L., Robarge, J., Philips, S., Cao, D., Skaar, T. C., Rae, J. M., Storniolo, A. M., Flockhart, D. A., Hayes, D. F., & Stearns, V. (2010). Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. British Journal of Cancer, 102(2), 294-300. https://doi.org/10.1038/sj.bjc.6605460